Nurix Therapeutics, Inc. NRIX Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s deferred revenue, net of current portion?
- Nurix Therapeutics, Inc. (NRIX) reported deferred revenue, net of current portion of $7.59M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s deferred revenue, net of current portion changed year-over-year?
- Nurix Therapeutics, Inc.'s deferred revenue, net of current portion decreased by 68.6% year-over-year, from $24.15M to $7.59M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s deferred revenue, net of current portion has grown at a -30.3% compound annual growth rate (CAGR), from $60.69M to $10.01M.